Skip to content
OpenCapital
Get started

Tarsus Pharmaceuticals, Inc. TARS Q2 2025 earnings

Reported August 6, 2025 · After market close

Revenue$102.7MMiss by $10.4M
EPS-$0.48Miss by $0.15
Revenue estimate$113.0M
EPS estimate-$0.33

Next report

Aug 6, 2026 (In 1 week)
Revenue estimate$169.1M
EPS estimate-$0.21

Financials

Q2 2025

Income statement

See full
Revenue$102.7M+152%
Operating income-$22.2M+33.4%
Net income-$20.3M+38.9%
EPS (diluted)-$0.48+45.5%

Balance sheet

See full
Cash & equivalents$99.2M-45.2%
Total debt$72.4M-1.6%
Total equity$332.6M+31.9%
Total assets$495.0M+31.4%

Cash flow

See full
Operating cash flow-$29.4M-104%
CapEx$1.0M-3.7%
Free cash flow-$30.4M-96.8%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$1.74B+81.3%
Enterprise value$1.71B+101%
P/S5.9×-5.6×

Profitability

See full
Operating margin-33.2%-15.0pp
Net margin-31.1%-14.1pp
FCF margin-28%-12.6pp

Returns & leverage

See full
Return on equity-31.5%-11.6pp
Debt / equity0.2×-0.1×
Current ratio5.3×-1.8×

Segments

By segment

See full
Reportable Segment$102.7M+152%

Versus estimates

Revenue

Q1 2026$162.1MBeat by $12.5MQ4 2025$151.7MBeat by $7.1MQ3 2025$118.7MMiss by $25.9M
Q2 2025$102.7MMiss by $10.4M
Q1 2025$78.3MMiss by $20.8MQ4 2024$66.4MBeat by $2.0M

Diluted EPS

Q1 2026-$0.16Beat by $0.24Q4 2025-$0.20Miss by $0.10Q3 2025-$0.30Beat by $0.05
Q2 2025-$0.48Miss by $0.15
Q1 2025-$0.64Beat by $0.05Q4 2024-$0.60Beat by $0.08

Ask the moment Tarsus Pharmaceuticals, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Tarsus Pharmaceuticals, Inc. report Q2 2025 earnings?
Tarsus Pharmaceuticals, Inc. (TARS) reported Q2 2025 earnings on August 6, 2025 after market close.
What were Tarsus Pharmaceuticals, Inc.'s Q2 2025 revenue and EPS?
Tarsus Pharmaceuticals, Inc. reported revenue of $102.7M and eps of $-0.48 for Q2 2025.
Did Tarsus Pharmaceuticals, Inc. beat estimates in Q2 2025?
Revenue missed the consensus estimate of $113.0M by $10.4M. EPS missed the consensus estimate of $-0.33 by $0.15.
How did Tarsus Pharmaceuticals, Inc.'s Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 151.5% from $40.8M a year earlier and eps grew 45.5% from $-0.88.
Where can I find Tarsus Pharmaceuticals, Inc.'s Q2 2025 SEC filings?
You can read the 10-Q periodic report (0001819790-25-000108) directly on SEC EDGAR. The filing index links above go to sec.gov.